Our research and development strategy
Supporting the long-term goal of eradicating malaria
MVI's research and development (R&D) strategy supports the long-term goal of eradicating malaria. The strategy aims to build on the success of GlaxoSmithKline Biologicals' RTS,S vaccine candidate that is now in the final stage of development in seven African countries. The strategy also includes approaches that seek to block malaria transmission and approaches that use weakened, whole parasites to protect against the disease.
MVI's R&D projects largely focus on Plasmodium falciparum, the most destructive malaria parasite that is found mainly in Africa. However, to further support efforts to eradicate malaria, MVI is increasing its focus on Plasmodium vivax, which causes a less severe—but more widespread—form of malaria. MVI's P. vivax program may yield candidates suitable for use in combination with those targeting P. falciparum.
Most new projects come to MVI as preclinical feasibility studies, with only a limited number advancing to full portfolio programs on a clinical track. This approach is an effective way to replenish MVI's portfolio and to maximize the program's potential for success.
In addition to providing direct support for vaccine development, MVI also invests in evaluation technologies to assess the potential efficacy of vaccine components. This is a critical component of MVI's R&D strategy and one that under-girds all vaccine development projects. MVI is also engaged in the process of defining acceptable vaccine product characteristics by developing target product profiles for each vaccine candidate and for potential candidates.